Phaseline

Targets › CHRM

CHRM: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Oncology.

Open in Phaseline: the race on CHRM, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Susan E. BatesBethanechol
Muscarinic acetylcholine receptor agonist (parasympathomimetic agent)
CHRMPhase 2Pancreas Cancer–

Conditions

Pancreas Cancer (1)

Modalities

small molecule (1)

Companies

Susan E. Bates (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.